Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide.
The company operates in two segments, EVT Execute and EVT Innovate.
The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
The EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc.
The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; and a strategic collaboration with Ildong Pharmaceutical Co., Ltd.
The company was founded in 1993 and is headquartered in Hamburg, Germany.